Literature DB >> 2662710

Primary chromosome abnormalities in human neoplasia.

S Heim1, F Mitelman.   

Abstract

At the cellular level, cancer is a genetic disease; genetic changes in somatic cells are essential events in neoplasia. In a majority of cases these changes involve large enough blocks of genetic material to be visible in the microscope. The chromosome aberrations in neoplastic disorders are probably of three kinds: (1) primary abnormalities, which are essential steps in establishing the tumor; (2) secondary abnormalities, which develop only after the tumor has developed, but which nevertheless may be important in tumor progression; and (3) cytogenetic noise, which is the background level of nonconsequential aberrations. These latter changes are, in contrast to the primary and secondary changes, randomly distributed throughout the genome. The primary abnormalities, of which several dozens have now been identified, are mostly strictly correlated with particular diseases and even with histopathological subtypes within a given disease. This has been evident in the leukemias for some years already, and information now accumulating on solid tumor karyology indicates a similar situation. Clonal chromosome abnormalities are a feature of both benign and malignant neoplasms, although the changes are often less massive in the former. Apart from being clinically useful as a diagnostic technique and an aid in prognostication, tumor cytogenetics also plays a role in identifying those genomic sites which harbor genes essential in the pathogenesis of neoplastic lesions. So far, two functionally different classes of directly cancer-relevant genes have been detected, the oncogenes and antioncogenes. There is every reason to believe that future investigations with cytogenetic and recombinant DNA methods will add to our knowledge of the biology of human neoplasia, in those tumor types where the characteristic genetic change is already partially known, and by identifying hitherto unknown karyotypic abnormalities.

Entities:  

Mesh:

Year:  1989        PMID: 2662710     DOI: 10.1016/s0065-230x(08)60209-2

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  7 in total

1.  A genetic linkage map of mouse chromosome 10: localization of eighteen molecular markers using a single interspecific backcross.

Authors:  M J Justice; L D Siracusa; D J Gilbert; N Heisterkamp; J Groffen; K Chada; C M Silan; N G Copeland; N A Jenkins
Journal:  Genetics       Date:  1990-08       Impact factor: 4.562

2.  Stable karyotypes in epithelial cancer cell lines despite high rates of ongoing structural and numerical chromosomal instability.

Authors:  Anna V Roschke; Kristen Stover; Giovanni Tonon; Alejandro A Schäffer; Ilan R Kirsch
Journal:  Neoplasia       Date:  2002 Jan-Feb       Impact factor: 5.715

Review 3.  Array-CGH and breast cancer.

Authors:  Erik H van Beers; Petra M Nederlof
Journal:  Breast Cancer Res       Date:  2006-06-30       Impact factor: 6.466

4.  Chromosomal aberrations in benign and malignant bilharzia-associated bladder lesions analyzed by comparative genomic hybridization.

Authors:  Imad Fadl-Elmula; Soili Kytola; Mona E L Leithy; Mohamed Abdel-Hameed; Nils Mandahl; Atif Elagib; Muntaser Ibrahim; Catharina Larsson; Sverre Heim
Journal:  BMC Cancer       Date:  2002-03-22       Impact factor: 4.430

5.  Reverting to single-cell biology: The predictions of the atavism theory of cancer.

Authors:  Kimberly J Bussey; Paul C W Davies
Journal:  Prog Biophys Mol Biol       Date:  2021-08-08       Impact factor: 3.667

6.  Aneuploidy prediction and tumor classification with heterogeneous hidden conditional random fields.

Authors:  Zafer Barutcuoglu; Edoardo M Airoldi; Vanessa Dumeaux; Robert E Schapire; Olga G Troyanskaya
Journal:  Bioinformatics       Date:  2008-12-03       Impact factor: 6.937

7.  Phenotypic and genotypic lineage switch of a lymphoma with shared chromosome translocation and T-cell receptor gamma gene rearrangement.

Authors:  K Yamamoto; H Osada; M Seto; M Ogura; H Suzuki; K R Utsumi; A Oyama; Y Ariyoshi; S Nakamura; S Kurita
Journal:  Jpn J Cancer Res       Date:  1992-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.